Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
Crossref DOI link: https://doi.org/10.1038/bcj.2015.77
Published Online: 2015-10-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhou, A
Knoche, E M
Engle, E K
Fisher, D A C
Oh, S T
Text and Data Mining valid from 2015-10-02
Version of Record valid from 2015-10-02
Article History
First Online: 2 October 2015
Competing interests
: The authors declare no conflict of interest.